<unk>  acts as an ATP-competitive RAF kinase inhibitor, decreasing ERK phosphorylation and down-regulation of CyclinD1. This arrests the cell cycle in G1 phase, inducing senescence without apoptosis. Therefore, it is only effective in melanomas with a BRAF mutation, which make up 50% of all melanomas. The plasma elimination half-life of<unk>  is approximately 6 hours, occurring mainly through metabolism via cytochrome P450 enzymes.
Encorafenib
Sorafenib
Regorafenib
Tucatinib
Capmatinib
Afatinib
Neratinib
Lapatinib